Yana Dekempeneer

Yana Dekempeneer
Vrije Universiteit Brussel | VUB · In vivo Cellular and Molecular Imaging Laboratory (ICMIC)

Master of Science

About

10
Publications
1,300
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
201
Citations
Citations since 2017
9 Research Items
199 Citations
201720182019202020212022202301020304050
201720182019202020212022202301020304050
201720182019202020212022202301020304050
201720182019202020212022202301020304050
Introduction
Yana Dekempeneer currently works at the In vivo Cellular and Molecular Imaging Laboratory (ICMIC) , Vrije Universiteit Brussel. Yana does research in Immunology, Cell Biology and Clinical Pharmacology. Their most recent publication is 'Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle'.

Publications

Publications (10)
Article
Full-text available
Human epidermal growth factor receptor type 2 (HER2) is overexpressed in various cancers; thus, HER2-targeting single-domain antibodies (sdAbs) could offer a useful platform for radioimmunotherapy. In this study, we optimized the labeling of an anti-HER2-sdAb with the α-particle-emitter 225Ac through a DOTA-derivative. The formed radioconjugate was...
Article
Targeted alpha-particle therapy (TAT) might be a relevant therapeutic strategy to circumvent resistance to conventional therapies in the case of HER2-positive metastatic cancer. Single-domain antibody fragments (sdAb) are promising vehicles for TAT due to their excellent in vivo properties, high target affinity and fast clearance kinetics. This stu...
Article
Full-text available
HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties for detecting and treating cancerous lesions in v...
Article
The use of nanobodies (Nbs) as vehicles in targeted alpha therapy (TAT) has gained great interest due to their excellent properties. They combine high in vivo affinity and specificity of binding with fast kinetics. This research investigates a novel targeted therapy that combines the α-particle emitter astatine-211 (211At) and the anti-HER2 Nb 2Rs1...
Article
Introduction: The combination of a targeted biomolecule that specifically defines the target and a radionuclide that delivers a cytotoxic payload offers a specific way to destroy cancer cells. Targeted radionuclide therapy (TRNT) aims to deliver cytotoxic radiation to cancer cells and causes minimal toxicity to surrounding healthy tissues. Recent...

Network

Cited By